Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible.

1 Indeed, the PARAGON-HF study recently showed a trend towards better clinical outcome in chronic renal failure patients treated with sacubitril/valsartan than valsartan itself, especially in the lower end of the EF spectrum, in women, in patients recently hospitalized for heart failure and in those with high sensitivity troponin values at baseline.

also in 53,322 other papers

However, although there was a 9% advantage in CVD reduction, it did not reach statistical significance.

also in 111,027 other papers